Home > Cardiology > EHRA 2022 > Developments in Devices > RESET: No survival benefit of CRT-defibrillator over CRT-pacemaker in heart failure

RESET: No survival benefit of CRT-defibrillator over CRT-pacemaker in heart failure

Presented By
Prof. Nikolaos Dagres, Heart Center Leipzig, Germany
Presented by
Nikolaos Dagres Heart Center Leipzig at University of Leipzig
Conference
EHRA 2022
Trial
RESET-CRT
Doi
https://doi.org/10.55788/4717cbf3
In patients with heart failure (HF) and an indication for cardiac resynchronisation therapy (CRT), patients who had a CRT-defibrillator (D) device did not show a survival benefit over patients who had a CRT-pacemaker (P) device. The results of the observational part of the RESET-CRT project further warrant the ongoing randomised part of the RESET-CRT project comparing CRT-D and CRT-P devices in patients with HF. “Should patients with HF and an indication for CRT receive a defibrillator?” asked Prof. Nikolaos Dagres (Heart Center Leipzig, Germany) [1,2]. Since the risk of sudden cardiac death in this population has decreased in recent years due to improved medication, this issue has come into question [2]. The existing evidence on this topic is conflicting. A post-hoc analysis of the COMPANION trial (NCT00180258) suggested that CRT-D reduced all-cause mort...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on